Sarepta Therapeutics Q2 2024 Adj. EPS $0.44 Beats $0.01 Estimate, Sales $362.931M Miss $391.406M Estimate
Sarepta Therapeutics Q2 2024 Adj. EPS $0.44 Beats $0.01 Estimate, Sales $362.931M Miss $391.406M Estimate
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.01 by 4300 percent. The company reported quarterly sales of $362.931 million which missed the analyst consensus estimate of $391.406 million by 7.28 percent. This is a 38.93 percent increase over sales of $261.238 million the same period last year. Provided revenue guidance of $2.9-$3.1 billion for fiscal year 2025, below analyst expectations of $3.241 billion. The midpoint of the guidance range represents a 3.7% shortfall compared to the consensus estimate.
Sarepta Therapeutics（納斯達克：Sarepta Therapeutics）報告顯示，每股收益爲0.44美元，超出分析師的1美分預期4300%。公司報告的季度銷售額爲362931萬美元，低於分析師對391406萬美元的預期7.28%。這是與去年同期的261238萬美元相比增長38.93%。提供了2025財年2.9-31億美元的營業收入指導，低於分析師對32.41億美元的預期。指導範圍的中點與共識預期相比有3.7%的差距。